The FDA has again delayed its review of Pfizer’s Xenjanz in ankylosing spondylitis, according to a news release from the drugmaker. The JAK inhibitor was previously found to increase the risks of serious heart problems and certain cancers compared to rheumatoid arthritis patients on TNF inhibitors. For the treatment of rheumatoid arthritis, Xeljanz currently holds covered or better status for 73% of all insured lives under the pharmacy benefit. 50.7% of covered lives have preferred access to Xeljanz, with utilization management restrictions applied in most cases.
SOURCE: MMIT Analytics, as of 7/26/21